A new drug for multiple sclerosis (MS), an intractable disease characterized by a high relapse rate, has been introduced to the market. Roche's Ocrevus was approved in Korea for the treatment of relapsing-remitting MS as well as primary progressive MS, for which there had been no treatment options available. Medical experts have expressed the importance of starting treatment with a high-potency agent early in the disease to prevent relapses.

On the 18th, Roche Korea held a press conference at the Lotte Hotel in Jung-gu, Seoul, to celebrate the approval of Ocrevus (ocrelizumab) as a treatment for multiple sclerosis in Korea. Ocrevus was approved in Korea on March 13 as an autoimmune disease trea